Companies Macrogenics Inc
Macrogenics (MGNX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Macrogenics Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers21st pct.Of 16 peer CEOs
CEO pay, last three years
- $2,078,854FY2025
CEO total pay was $2,078,854 in fiscal 2025; the brief holds no earlier figure for this CEO.
FY2025: salary $561,568 · bonus $150,000 · stock awards $52,000 · option awards $1,049,386
Executives and directors
Eric Risser · CEOJames Karrels · CFOScott Koenig · CEOEzio Bonvini · SVPDavid Stump · Independent DirectorEdward Hurwitz · Independent DirectorFederica O'Brien · Independent DirectorJay Siegel · Independent DirectorKaren Ferrante · Independent DirectorMargaret Liu · Independent DirectorMeenu Chhabra Karson · Independent DirectorScott Jackson · Independent DirectorWilliam Heiden · Independent Director
Frequently asked questions
Who was the highest-paid executive at Macrogenics Inc in fiscal 2025?
As disclosed, Eric Risser (President, Chief Executive Officer and Director) was the highest-paid executive at Macrogenics Inc in fiscal 2025, with total compensation of $2,078,854.
How does Macrogenics Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Eric Risser's total compensation ranked at the 21st percentile of Macrogenics Inc's disclosed peer group.
How did shareholders vote on Macrogenics Inc's executive compensation?
As disclosed, 98.06% of shareholders supported Macrogenics Inc's executive compensation in the latest say-on-pay vote.
How much does Macrogenics Inc spend in total on board compensation for fiscal 2025?
As disclosed, Macrogenics Inc reported total board compensation of $591,740 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Eric Risser | $561,568 | $150,000 | $52,000 | $1,049,386 | $251,900 | $0 | $14,000 | $2,078,854 |
| President, Chief Executive Officer and Director | ||||||||
| Ezio Bonvini | 533,200 | 150,000 | 54,600 | 288,038 | 184,200 | 0 | 14,000 | 1,224,038 |
| Senior Vice President, Research and Chief Scientific Officer | ||||||||
| James Karrels | 506,548 | 150,000 | 49,400 | 254,284 | 175,000 | 0 | 14,000 | 1,149,232 |
| Senior Vice President and Chief Financial Officer | ||||||||
| Scott Koenig | 477,120 | 0 | 0 | 0 | 0 | 0 | 475,841 | 952,961 |
| Former Chief Executive Officer and current Director | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Eric Risser | $2,078,854 | — | — | — |
| Ezio Bonvini | 1,224,038 | — | — | — |
| James Karrels | 1,149,232 | 2,365,543 | 1,578,744 | ↓ −1,216,311 |
| Scott Koenig | 952,961 | 6,403,448 | 3,705,825 | ↓ −5,450,487 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
MacroGenics executive compensation program, overseen by the Human Capital Management Committee, is designed to attract, retain and reward highly qualified talent at the senior executive level, in a very competitive market, while ensuring individual and corporate accountability to achieve the Company's mission, vision, and goals.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Ezio Bonvini | Option | 4,688 | 10.15 | — |
| James Karrels | Option | 8,750 | 10.15 | — |
| Scott Koenig | Option | 10,074 | 10.15 | — |
| Eric Risser | Option | 10,625 | 10.15 | — |
| James Karrels | RSU | 14,999 | — | 24,148 |
| Eric Risser | RSU | 16,665 | — | 26,831 |
| Ezio Bonvini | RSU | 16,665 | — | 26,831 |
| James Karrels | RSU | 19,000 | — | 30,590 |
| James Karrels | RSU | 19,998 | — | 32,197 |
| Eric Risser | RSU | 20,000 | — | 32,200 |
| Ezio Bonvini | RSU | 21,000 | — | 33,810 |
| Scott Koenig | RSU | 21,165 | — | 34,076 |
| Eric Risser | RSU | 22,332 | — | 35,955 |
| Ezio Bonvini | RSU | 22,332 | — | 35,955 |
| Scott Koenig | RSU | 31,663 | — | 50,977 |
| James Karrels | Option | 45,000 | 18.3 | — |
| Eric Risser | Option | 50,625 | 18.3 | — |
| Ezio Bonvini | Option | 50,625 | 18.3 | — |
| James Karrels | Option | 56,250 | 4.82 | — |
| Eric Risser | Option | 62,500 | 4.82 | — |
| Ezio Bonvini | Option | 62,500 | 4.82 | — |
| Scott Koenig | Option | 66,385 | 18.3 | — |
| Scott Koenig | Option | 71,720 | 4.82 | — |
| James Karrels | Option | 91,813 | 2.6 | — |
| Eric Risser | Option | 97,500 | 2.6 | — |
| Ezio Bonvini | Option | 104,000 | 2.6 | — |
| Eric Risser | Option | 550,000 | 1.66 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| William HeidenIndependent · Audit · Human Capital Management | $118,125 | $5,587 | $21,318 | — | $0 | $145,030 |
| Federica O'BrienIndependent · Audit (Chair) · Human Capital Management | 20,625 | 5,587 | 84,265 | — | 0 | 110,477 |
| Jay SiegelIndependent · Human Capital Management · Science and Technology (Chair) | 79,375 | 5,587 | 21,318 | — | 0 | 106,280 |
| David StumpIndependent · Nominating and Corporate Governance (Chair) · Science and Technology | 68,958 | 5,587 | 21,318 | — | 0 | 95,863 |
| Karen FerranteIndependent · Nominating and Corporate Governance · Science and Technology | 58,958 | 5,587 | 21,318 | — | 0 | 85,863 |
| Edward HurwitzIndependent · Nominating and Corporate Governance · Science and Technology | 58,958 | 5,587 | 21,318 | — | 0 | 85,863 |
| Margaret LiuIndependent · Nominating and Corporate Governance · Science and Technology | 58,958 | 5,587 | 21,318 | — | 0 | 85,863 |
| Scott JacksonIndependent · Audit | 55,000 | 5,587 | 21,318 | — | 0 | 81,905 |
| Meenu Chhabra KarsonIndependent · Audit · Human Capital Management (Chair) | 5,625 | 5,587 | 69,005 | — | 0 | 80,217 |
| Scott KoenigIndependent | 16,875 | 0 | 0 | — | 0 | 16,875 |
| Eric RisserEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | $135,000 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $541,457 |
| Equity awards (grant-date value) | $50,283 |
| All other compensation | $0 |
| Total cost of the board | $591,740 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Macrogenics as a peer
Companies that benchmark against MGNX
18 companies name MGNX as a compensation peer
The list of companies that name MGNX as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
TSVT 2seventy bioADAP Adaptimmune TherapeuticsAGEN Agenus, Inc.RCUS Arcus BiosciencesFATE Fate TherapeuticsINO Inovio PharmaceuticalsITOS iTeos TherapeuticsKPTI Karyopharm TherapeuticsMRSN Mersana TherapeuticsRIGL Rigel PharmaceuticalsXNCR Xencor, Inc.YMAB Y-mAbs TherapeuticsZYME Zymeworks, Inc. G1 TherapeuticsPGEN PrecigenCOGT Cogent Biosciences
Peer reciprocity
The companies Macrogenics Inc names as compensation peers that name it back in their own disclosed peer groups.
Adaptimmune Therapeutics (ADAP)78Agenus, Inc. (AGEN)79Fate Therapeutics (FATE)80Rigel Pharmaceuticals (RIGL)81Y-mAbs Therapeutics (YMAB)82Zymeworks, Inc. (ZYME)83
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cogent Biosciences | 2025 | Andrew Robbins | $724,554 | $12,993,250 | $13,447,680 | $561,600 | $27,762,684 |
| 2 | Arcus Biosciences | 2025 | Terry Rosen | 775,000 | 2,199,450 | 6,008,860 | 658,750 | 9,656,813 |
| 3 | Zymeworks, Inc. | 2025 | Kenneth Galbraith | 656,763 | 2,538,240 | 2,366,565 | 340,990 | 6,613,180 |
| 4 | iTeos Therapeutics | 2024 | Michel Detheux | 628,684 | 0 | 4,965,264 | 421,014 | 6,085,657 |
| 5 | Xencor, Inc. | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 6 | Precigen | 2025 | Helen Sabzevari | 1,000,000 | 2,215,000 | 1,069,200 | 1,049,997 | 5,354,329 |
| 7 | Rigel Pharmaceuticals | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 8 | Y-mAbs Therapeutics | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 9 | Karyopharm Therapeutics | 2025 | Richard Paulson | 770,000 | 838,996 | 241,544 | 350,350 | 2,320,902 |
| 10 | Fate Therapeutics | 2025 | Bahram Valamehr | 600,000 | 0 | 1,283,868 | 360,000 | 2,248,568 |
| 11 | Adaptimmune Therapeutics | 2024 | Adrian Rawcliffe | 676,000 | 0 | 1,065,820 | 324,480 | 2,109,075 |
| 12 | Macrogenics Inc | 2025 | Eric Risser | 561,568 | 52,000 | 1,049,386 | 251,900 | 2,078,854 |
| 13 | Mersana Therapeutics | 2024 | Michael Huber | 632,500 | 133,635 | 518,044 | 322,575 | 1,613,754 |
| 14 | Inovio Pharmaceuticals | 2025 | Jacqueline Shea | 728,000 | 346,101 | 351,955 | 144,144 | 1,587,155 |
| 15 | Agenus, Inc. | 2025 | Garo Armen | 715,260 | 0 | 141,000 | 0 | 1,350,325 |
| — | 2seventy bio | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Macrogenics Inc | 85% | not disclosed | not disclosed | Alpine Rewards, LLC |
| 2seventy bio | not disclosed | not disclosed | not disclosed | not disclosed |
| Adaptimmune Therapeutics | 80% | Options 75 · RSU 25 | not disclosed | Pearl Meyer |
| Agenus, Inc. | 125% | Options 100 | not disclosed | Aon Radford |
| Arcus Biosciences | 100% | Options 67 · RSU 33 | not disclosed | Radford |
| Cogent Biosciences | 135% | not disclosed | No | Compensia |
| Fate Therapeutics | 100% | Options 100 | No | Aon's Human Capital Solutions practice (Radford) |
| Inovio Pharmaceuticals | 33% | not disclosed | Yes — Relative TSR | Aon (Human Capital Solutions practice) |
| iTeos Therapeutics | not disclosed | not disclosed | not disclosed | Radford |
| Karyopharm Therapeutics | 90% | not disclosed | Yes — Relative TSR | Alpine, WTW |
| Mersana Therapeutics | not disclosed | Option 75 · RSU 25 | not disclosed | Pearl Meyer & Partners, LLC |
| Precigen | 140% | not disclosed | not disclosed | Aon |
| Rigel Pharmaceuticals | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| Xencor, Inc. | 110% | Options 60 · RSU 40 | not disclosed | Aon |
| Y-mAbs Therapeutics | 85.6% | not disclosed | No | Aon |
| Zymeworks, Inc. | not disclosed | Option 50 · RSU 50 | not disclosed | Aon plc (Talent Solutions practice) |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-19 | 26,624,952 | 526,125 | 195,228 | 98.06% | Passed |
| 2025 | 2025-05-21 | 42,433,276 | 1,382,356 | 17,656 | 96.85% | Passed |
| 2024 | 2024-05-21 | 49,530,270 | 2,225,779 | 12,170 | 95.7% | Passed |
| 2023 | 2023-05-31 | 43,633,412 | 5,433,960 | 7,833 | 88.93% | Passed |
| 2022 | 2022-05-19 | 44,883,740 | 1,964,657 | 8,171 | 95.81% | Passed |
| 2021 | 2021-05-13 | 48,895,827 | 1,660,237 | 21,800 | 96.72% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-19 | 98.06%a |
| 2025 | 2025-05-21 | 96.85%b |
| 2024 | 2024-05-21 | 95.7%c |
a. Approved under the standard stated in the filing — “Abstentions are not considered votes cast and, therefore, will have no effect on the vote outcome.”.
b. Approved under the standard stated in the filing — “Abstentions are not considered votes cast and, therefore, will have no effect on the vote outcome.”.
c. Approved under the standard stated in the filing — “Abstentions are not considered votes cast and, therefore, will have no effect on the vote outcome.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Karen Ferrante | Director | 2026-05-18 | D | 3,750 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Hurwitz | Director | 2026-05-18 | A | 3,750 | — | — | Common | Form 4 ↗ |
| Meenu Chhabra | Director | 2026-05-18 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret Liu | Director | 2026-05-18 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret Liu | Director | 2026-05-18 | A | 3,750 | — | — | Common | Form 4 ↗ |
| Jay Siegel | Director | 2026-05-18 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Heiden | Director | 2026-05-18 | A | 3,750 | — | — | Common | Form 4 ↗ |
| Federica O'Brien | Director | 2026-05-18 | A | 3,750 | — | — | Common | Form 4 ↗ |
| Karen Ferrante | Director | 2026-05-18 | A | 3,750 | — | — | Common | Form 4 ↗ |
| David Stump | Director | 2026-05-18 | A | 3,750 | — | — | Common | Form 4 ↗ |
| Meenu Chhabra | Director | 2026-05-18 | A | 3,750 | — | — | Common | Form 4 ↗ |
| Jay Siegel | Director | 2026-05-18 | A | 3,750 | — | — | Common | Form 4 ↗ |
| Scott Jackson | Director | 2026-05-18 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Jackson | Director | 2026-05-18 | A | 3,750 | — | — | Common | Form 4 ↗ |
| Federica O'Brien | Director | 2026-05-18 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Hurwitz | Director | 2026-05-18 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Stump | Director | 2026-05-18 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Heiden | Director | 2026-05-18 | D | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Koenig | Director | 2026-05-19 | A | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Ferrante | Director | 2026-05-19 | A | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Koenig | Director | 2026-05-19 | A | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Karen Ferrante | Director | 2026-05-19 | A | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Stump | Director | 2026-05-19 | A | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Hurwitz | Director | 2026-05-19 | A | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Meenu Chhabra | Director | 2026-05-19 | A | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret Liu | Director | 2026-05-19 | A | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret Liu | Director | 2026-05-19 | A | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Jackson | Director | 2026-05-19 | A | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Jackson | Director | 2026-05-19 | A | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Stump | Director | 2026-05-19 | A | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Meenu Chhabra | Director | 2026-05-19 | A | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Edward Hurwitz | Director | 2026-05-19 | A | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Federica O'Brien | Director | 2026-05-19 | A | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Federica O'Brien | Director | 2026-05-19 | A | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Heiden | Director | 2026-05-19 | A | 22,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Heiden | Director | 2026-05-19 | A | 3,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ezio Bonvini | Sr VP, Research & CSO | 2026-08-17 | A | 40,000 | 3 | 104,000 | Common | Form 4 ↗ |
| Ezio Bonvini | Sr VP, Research & CSO | 2026-08-17 | D | 40,000 | 3 | 104,000 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stuart Peters | Senior VP, GC, and Secretary | 2026-08-19 | D | 31,105 | 4 | 129,086 | Common | Form 4 ↗ |
| Ezio Bonvini | Sr VP, Research & CSO | 2026-10-06 | D | 8,000 | 3 | 20,800 | Derivative, Class A Common | Form 4 ↗ |
| Ezio Bonvini | Sr VP, Research & CSO | 2026-10-06 | A | 8,000 | 3 | 20,800 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (83 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Eric Risser. DEF 14A, filed 2026-04-08. Section “Summary Compensation Table” · page 40. As printed: 2,078,854. View filing ↗
- Section 01, Ezio Bonvini. DEF 14A, filed 2026-04-08. Section “Summary Compensation Table”. As printed: 1,224,038. View filing ↗
- Section 01, James Karrels. DEF 14A, filed 2026-04-08. Section “Summary Compensation Table”. As printed: 1,149,232. View filing ↗
- Section 01, Scott Koenig. DEF 14A, filed 2026-04-08. Section “Summary Compensation Table”. As printed: 952,961. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-09. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, William Heiden. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 145,030. View filing ↗
- Section 08, Federica O'Brien. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 110,477. View filing ↗
- Section 08, Jay Siegel. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 106,280. View filing ↗
- Section 08, David Stump. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 95,863. View filing ↗
- Section 08, Karen Ferrante. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 85,863. View filing ↗
- Section 08, Edward Hurwitz. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 85,863. View filing ↗
- Section 08, Margaret Liu. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 85,863. View filing ↗
- Section 08, Scott Jackson. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 81,905. View filing ↗
- Section 08, Meenu Chhabra Karson. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 80,217. View filing ↗
- Section 08, Scott Koenig. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 16,875. View filing ↗
- Section 08, Eric Risser. DEF 14A, filed 2026-04-08. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Karen Ferrante 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Hurwitz 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meenu Chhabra 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Margaret Liu 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Margaret Liu 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jay Siegel 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Heiden 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Federica O'Brien 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Ferrante 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Stump 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meenu Chhabra 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jay Siegel 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Jackson 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Jackson 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Federica O'Brien 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Hurwitz 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Stump 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Heiden 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Koenig 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Ferrante 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Koenig 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Karen Ferrante 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Stump 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Hurwitz 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meenu Chhabra 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Margaret Liu 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Margaret Liu 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Jackson 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Jackson 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Stump 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Meenu Chhabra 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward Hurwitz 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Federica O'Brien 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Federica O'Brien 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Heiden 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Heiden 2026-05-19. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ezio Bonvini 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ezio Bonvini 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stuart Peters 2026-08-19. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ezio Bonvini 2026-10-06. Form 4, filed 2026-10-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ezio Bonvini 2026-10-06. Form 4, filed 2026-10-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-20. Item 5.07 · say-on-pay result. As reported: 98.06% (votes for as printed: 26,624,952). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-22. Item 5.07 · say-on-pay result. As reported: 96.85% (votes for as printed: 42,433,276). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-23. Item 5.07 · say-on-pay result. As reported: 95.7% (votes for as printed: 49,530,270). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 541,457 + equity 50,283 + all other 0 = 591,740, summed across the director compensation table rows.
- Cogent Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cogent Biosciences's own proxy. As printed: 27,762,684. View filing ↗
- Arcus Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. View filing ↗
- Zymeworks, Inc., Section 10b CEO total. DEF 14A, filed 2026-10-26. CEO total compensation as printed in Zymeworks, Inc.'s own proxy. As printed: 6,613,180. View filing ↗
- iTeos Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in iTeos Therapeutics's own proxy. As printed: 6,085,657. View filing ↗
- Xencor, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Xencor, Inc.'s own proxy. As printed: 5,521,205. View filing ↗
- Precigen, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Precigen's own proxy. As printed: 5,354,329. View filing ↗
- Rigel Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals's own proxy. As printed: 4,658,805. View filing ↗
- Y-mAbs Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-05-30. CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. View filing ↗
- Karyopharm Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Karyopharm Therapeutics's own proxy. As printed: 2,320,902. View filing ↗
- Fate Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Fate Therapeutics's own proxy. As printed: 2,248,568. View filing ↗
- Adaptimmune Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Adaptimmune Therapeutics's own proxy. As printed: 2,109,075. View filing ↗
- Macrogenics Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Macrogenics Inc's own proxy. As printed: 2,078,854. View filing ↗
- Mersana Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Mersana Therapeutics's own proxy. As printed: 1,613,754. View filing ↗
- Inovio Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Inovio Pharmaceuticals's own proxy. As printed: 1,587,155. View filing ↗
- Agenus, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Agenus, Inc.'s own proxy. As printed: 1,350,325. View filing ↗
- Section 10a, Adaptimmune Therapeutics reciprocity. DEF 14A. Adaptimmune Therapeutics names Macrogenics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Agenus, Inc. reciprocity. DEF 14A. Agenus, Inc. names Macrogenics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Fate Therapeutics reciprocity. DEF 14A. Fate Therapeutics names Macrogenics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Rigel Pharmaceuticals reciprocity. DEF 14A. Rigel Pharmaceuticals names Macrogenics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Y-mAbs Therapeutics reciprocity. DEF 14A. Y-mAbs Therapeutics names Macrogenics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Zymeworks, Inc. reciprocity. DEF 14A. Zymeworks, Inc. names Macrogenics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗